Back to search

Switzerland· 56936002

Primovist 0.25 mmol/ml, Injektionslösung

A gadoxetsäure product containing dinatrii gadoxetas, registered in Switzerland by Bayer (Schweiz) AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat B (Swissmedic)ATC V08CA10

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedPrimovist 0.25 mmol/ml, Injektionslös…ATCV08CA10REGISTER NO.56936002PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Gadoxetsäure is registered in 12 of 19 countries.

Countries holding a registration under ATC V08CA10 (gadoxetsäure), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 7 of them publish a price we can compare per daily dose

Gadoxetsäure · ATC V08CA10

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Swissmedic (Switzerland)
Active substance
dinatrii gadoxetas
Manufacturer
Bayer (Schweiz) AG
Country
Switzerland (CH)
ATC code
V08CA10
ATC class
Gadoxetsäure
Swissmedic category
B
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680569360024
    Fertspr 10 ml
    CHF 188.7

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

34 interactions on record for gadoxetsäure.

Graded by severity as the source publishes them — 34 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Gadoxetsäure · interactions on record

34 records

  • 34 moderate

Most severe, free to view

  • PindololC07AA03moderate
  • PropranololC07AA05moderate
  • TimololC07AA06moderate
  • SotalolC07AA07moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/a6ebdf9c-b288-4116-b69e-c34c646e6f0b
GET /v1/drugs/a6ebdf9c-b288-4116-b69e-c34c646e6f0b?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "dinatrii gadoxetas 181.43 mg",
  "valid_from": "2026-02-01",
  "limitations": null,
  "galenic_form": "Inj Lös 0.25 mmol/ml",
  "therapeutic_area": null,
  "sl_inclusion_date": "2006-05-01",
  "self_retention_pct": 10
}

See everything about gadoxetsäure.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.